Lyell Immunopharma, Inc.

LYEL

NASDAQ

Healthcare

Biotechnology

South San Francisco, CA, US300 employeeslyell.com

$21.20

+0.40(1.90%)

Mkt Cap $494M

$7.80

$38.60

52-Week Range

At a Glance

AI-generated

Lyell Immunopharma, Inc.

Revenue breakdown: Reportable Segment (100%).

8-K

Lyell Immunopharma, Inc. furnished its press release dated March 12, 2026, under Item 2.02 regarding results of operations via Exhibit 99.1. This disclosure provides key financial information relevant to investors.

$494M

Market Cap

$49.1K

Revenue

-$374M

Net Income

Employees300

Fundamentals

How The Business Makes Money

Revenue by Segment

Reportable Segment100%($227.0K)

Activity

What Changed Recently

Management Change

Mar 8, 2026

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers . On March 6,

Financial Results

Mar 11, 2026

, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934,

Peer Companies

Company	Price	Change	Market Cap	P/E
ALLOAllogene Therapeutics, In...	$2.50	-2.54%	$608M	-2.8
LRMRLarimar Therapeutics, Inc...	$4.76	+1.82%	$408M	-2.4
KYTXKyverna Therapeutics, Inc...	$8.85	+0.86%	$387M	-2.1
AMRNAmarin Corporation plc	$14.74	+0.68%	$305M	-156.5
CABACabaletta Bio, Inc.	$2.97	+10.82%	$286M	-1.2
ACIUAC Immune S.A.	$2.77	-0.72%	$282M	-3.3
SLNSilence Therapeutics plc	$5.88	+7.50%	$278M	-3.1
EDITEditas Medicine, Inc.	$2.68	+2.68%	$262M	-1.3

Analyst View

Company Profile

CIK0001806952

ISINUS55083R2031

CUSIP55083R203

Phone650 695 0677

Address201 Haskins Way, South San Francisco, CA, 94080, US

SEC EDGAR